Evidence-Based Eye Health Guide

AREDS and AREDS2 changed how researchers understand nutritional supplementation for age-related macular degeneration. This guide examines what the landmark studies actually found, who benefited, what changed between the two formulas, and what the evidence does — and does not — support.

Few nutrition studies have influenced the eye-supplement market as much as the Age-Related Eye Disease Study (AREDS) and its follow-up, AREDS2.

Sponsored by the U.S. National Eye Institute, these large clinical trials were created to answer an important question: could specific combinations of vitamins, minerals, and other nutrients help slow the progression of age-related eye disease?

The answer turned out to be more nuanced than many supplement labels and marketing claims suggest.

AREDS and AREDS2 did provide strong evidence that certain nutritional formulations can help reduce the risk of progression to advanced age-related macular degeneration (AMD) in particular groups of people. However, the studies did not show that eye supplements prevent AMD in healthy adults, restore lost vision, improve eyesight in everyone, or eliminate the need for regular eye care.

Understanding this distinction matters.

The original AREDS trial evaluated a combination containing vitamin C, vitamin E, beta-carotene, zinc, and copper. Researchers found that among people considered at relatively high risk of developing advanced AMD, the complete formulation reduced the risk of progression to advanced disease by approximately 25% over five years.

Those findings raised another question: could the formula be improved?

That question eventually led to AREDS2, a second major clinical trial involving more than 4,000 participants. Researchers examined whether adding lutein and zeaxanthin, omega-3 fatty acids, or both could provide additional protection. They also investigated whether beta-carotene could be removed and whether the amount of zinc could be reduced.

The results reshaped the formula.

While simply adding lutein and zeaxanthin or omega-3s to the original AREDS formulation did not produce a significant additional overall benefit in the study’s primary analysis, replacing beta-carotene with lutein and zeaxanthin proved particularly important. Beta-carotene had been associated with increased lung-cancer risk in smokers and former smokers, while lutein and zeaxanthin provided a safer alternative within the formulation.

Long-term follow-up strengthened the case for that change. A later National Eye Institute analysis reported that the AREDS2 formulation containing lutein and zeaxanthin instead of beta-carotene maintained the protective effect against AMD progression while avoiding the beta-carotene-related lung-cancer concern.

Today, the term “AREDS2 formula” appears frequently on eye-health supplements.

But seeing those words on a bottle does not automatically mean that the product is appropriate for everyone — or that every nutrient associated with eye health has been proven to prevent vision problems.

To understand what AREDS2 really means, we need to look at the original research carefully.

In this guide, we will examine:

• what the original AREDS trial was designed to investigate;
• what researchers actually discovered;
• why AREDS2 was conducted;
• why lutein and zeaxanthin replaced beta-carotene;
• what happened with omega-3 fatty acids and zinc;
• who benefited from the formulations;
• what the studies did not demonstrate;
• and how the findings should be interpreted when evaluating modern eye supplements.

The goal is not to promote a particular supplement.

It is to separate the actual clinical evidence from the much broader claims that sometimes surround it.

What Are AREDS and AREDS2?

AREDS stands for the Age-Related Eye Disease Study.

The study was sponsored by the National Eye Institute, part of the U.S. National Institutes of Health, and was designed to examine the natural progression of two major age-related eye conditions:

• age-related macular degeneration (AMD);
• cataracts.

Researchers were particularly interested in whether nutritional supplementation could influence how these conditions progressed over time.

The original AREDS trial enrolled 4,757 participants between the ages of 55 and 80.

Participants had varying levels of AMD, cataracts, or both, allowing researchers to observe how nutritional interventions affected people at different stages of eye disease.

The study was not simply testing whether vitamins were “good for the eyes.”

Instead, researchers compared specific supplement combinations and followed participants for several years to determine whether those combinations influenced measurable clinical outcomes.

Those outcomes included:

• progression to advanced AMD;
• central vision loss;
• progression of cataracts;
• and the need for cataract surgery.

That distinction is important because the AREDS trials were designed around specific diseases and specific patient populations, not general vision enhancement.

The Original AREDS Formulation

The original formulation included:

• Vitamin C — 500 mg
• Vitamin E — 400 IU
• Beta-carotene — 15 mg
• Zinc — 80 mg
• Copper — 2 mg

Copper was included because long-term supplementation with high amounts of zinc can interfere with copper absorption and potentially contribute to copper deficiency.

Researchers compared different combinations of antioxidants and zinc with placebo.

The most important finding emerged among participants who already had intermediate AMD or advanced AMD in one eye.

In these higher-risk participants, the full combination of antioxidants, zinc, and copper reduced the risk of progressing to advanced AMD by approximately 25% compared with placebo.

It also reduced the risk of central vision loss by about 19% in the same high-risk group.

These findings became the scientific foundation of the original AREDS formulation.

However, they also revealed one of the most commonly misunderstood aspects of the research.

AREDS Was Not a General Eye-Health Prevention Study

The benefit was not seen equally across everyone who participated.

According to the National Eye Institute, the formulation did not demonstrate a meaningful benefit for people with no AMD or early AMD.

Its strongest evidence applied to people who already had a particular level of AMD and were therefore at greater risk of disease progression.

In other words:

AREDS was primarily about slowing progression — not preventing AMD from developing in the first place.

That distinction remains essential when interpreting eye-supplement claims today.

What Did the Original AREDS Study Actually Find?

The original AREDS trial produced one of the most influential findings in modern nutritional eye research.

But the benefit was not universal.

Researchers found that the strongest effect occurred among participants who were already considered at relatively high risk of progressing to advanced age-related macular degeneration.

According to the National Eye Institute, participants with intermediate AMD or advanced AMD in one eye who received the complete AREDS combination of antioxidants, zinc, and copper experienced approximately a:

• 25% reduction in the risk of progression to advanced AMD
• 19% reduction in the risk of central vision loss

compared with participants receiving placebo.

Those numbers became the foundation of the AREDS formula and remain some of the most frequently cited statistics in discussions of eye supplements.

However, understanding what those percentages actually mean is essential.

A 25% reduction does not mean that 25% of participants had their AMD reversed.

It also does not mean that everyone taking the formulation had a 25% chance of improving their vision.

Instead, the finding refers to a relative reduction in the risk of disease progression within the higher-risk population studied.

That is a much more specific conclusion.

The Benefit Was Primarily About Slowing Progression

AREDS did not demonstrate that nutritional supplementation could restore retinal tissue already damaged by AMD.

Nor did it show that the formulation could recover vision that had already been lost.

The National Eye Institute emphasized this point when the findings were originally announced: the nutrients were not considered a cure for AMD and were not shown to restore vision already lost to the disease.

The purpose of the formulation was therefore better understood as risk modification.

For certain people with established AMD, the nutrients appeared to reduce the likelihood that the disease would progress to a more advanced stage over the study period.

That distinction may sound subtle, but it is fundamental.

There is a major difference between:

helping reduce the risk of disease progression

and

improving eyesight.

AREDS provided evidence for the first statement in a particular clinical population.

It did not establish the second as a general effect.

Who Benefited Most From AREDS?

The strongest evidence applied to people who already had significant signs of AMD.

In practical terms, the National Eye Institute identified the groups most likely to benefit as people with:

• intermediate AMD in one or both eyes, or
• advanced AMD in one eye with less advanced disease in the other eye.

By contrast, people who had no AMD or only early AMD did not show a meaningful benefit from the formulation.

This is one of the most important findings in the entire AREDS program.

It means that the evidence does not support the idea that everyone should take an AREDS-style supplement simply because they want to “protect their eyesight.”

The formulation was studied as a targeted intervention for people with specific stages of AMD.

Why Disease Stage Matters

AMD develops along a spectrum.

The condition can range from early structural changes in the retina to intermediate disease and eventually to advanced forms associated with substantial central vision loss.

One important feature doctors evaluate is the presence of drusen.

Drusen are yellow deposits that can develop beneath the retina. Small drusen are relatively common with aging, but larger or more numerous drusen can be associated with an increased risk of progression to advanced AMD.

In AREDS, researchers categorized participants according to the severity of retinal changes.

This allowed them to determine whether supplementation had different effects at different stages of disease.

The answer was clear:

the higher-risk groups experienced the meaningful benefit.

People without AMD or with only early disease did not obtain the same measurable protection.

That observation was so important that it directly influenced the design of the later AREDS2 trial.

AREDS2 did not enroll people without AMD or with early AMD because the original AREDS results had already shown no meaningful benefit in those populations.

Did AREDS Prevent AMD?

No.

This point deserves its own section because it is one of the most common misunderstandings surrounding AREDS supplements.

The National Eye Institute states that AREDS and AREDS2 supplements do not prevent AMD from developing.

The studies instead showed that, among certain people who already had intermediate disease, supplementation could reduce the risk that AMD would progress to an advanced stage.

That means a statement such as:

“AREDS2 prevents macular degeneration”

would overstate the evidence.

A more accurate interpretation would be:

“AREDS2 supplementation may help reduce the risk of progression to advanced AMD in certain people who already have intermediate AMD.”

That wording better reflects the clinical evidence.

What About People With Early AMD?

The results were also clear here.

People with early AMD did not demonstrate the same benefit seen in participants with intermediate disease.

The National Eye Institute continues to state that AREDS2 supplementation is not shown to prevent early AMD from progressing into intermediate AMD.

For people with early changes, regular eye examinations remain especially important because the condition can be monitored over time.

If the disease eventually reaches a stage where AREDS2 supplementation may be appropriate, that decision can then be discussed with an eye-care professional.

AREDS and Cataracts: Another Important Result

AREDS was not designed only around AMD.

Researchers were also investigating whether the antioxidant and mineral combinations could influence the development or progression of age-related cataracts.

The results were very different from those seen with AMD.

The original AREDS formulations did not significantly reduce the risk of cataract progression or cataract surgery.

This distinction is important because products marketed broadly for “eye health” sometimes combine evidence from different eye conditions as though they were interchangeable.

They are not.

A nutrient combination that influences the progression of AMD does not automatically prevent cataracts.

Similarly, evidence involving the retina cannot automatically be applied to the lens of the eye.

The eye contains multiple tissues, each with different biological functions and disease processes.

That is one reason evidence-based interpretation requires looking carefully at the specific condition being studied.

How Did the Different AREDS Formulations Perform?

The original AREDS study tested more than one supplementation strategy.

Researchers compared:

• antioxidants alone;
• zinc plus copper;
• antioxidants plus zinc and copper;
• and placebo.

Among the high-risk participants, the complete combination performed best.

According to the National Eye Institute, compared with placebo:

AREDS Intervention	Reduction in Progression to Advanced AMD	Reduction in Vision Loss
Antioxidants + zinc + copper	~25%	~19%
Zinc + copper	~21%	~11%
Antioxidants alone	~17%	~10%

These results helped establish the complete antioxidant-plus-zinc formulation as the original AREDS formula.

At the same time, they raised new questions.

Was beta-carotene really the best carotenoid to include?

Was the zinc dose higher than necessary?

Could other nutrients found naturally in the retina provide additional protection?

And what about omega-3 fatty acids, which observational research had linked with eye health?

Those unanswered questions became the foundation for the next major trial.

Why Was AREDS2 Needed?

By the time the original AREDS findings were published, researchers had good evidence that a particular combination of antioxidants and minerals could reduce AMD progression in certain high-risk individuals.

But science rarely stops after one successful trial.

Instead, new questions emerge.

Researchers wanted to know whether the original formula could be made safer, more effective, or both.

Three issues were particularly important.

1. Beta-Carotene Had Become a Concern

Beta-carotene was included in the original AREDS formula as an antioxidant.

However, separate large clinical trials had linked high-dose beta-carotene supplementation with an increased risk of lung cancer among smokers.

That created an obvious problem.

Many people at risk for AMD were current or former smokers, meaning that a widely used eye-health formulation containing beta-carotene might not be appropriate for part of the population it was intended to help.

AREDS2 therefore provided an opportunity to test whether beta-carotene could be replaced.

The obvious candidates were lutein and zeaxanthin.

Unlike beta-carotene, lutein and zeaxanthin naturally accumulate in the retina, particularly in the macula, where they form part of the macular pigment.

2. Lutein and Zeaxanthin Were Biologically Interesting

Lutein and zeaxanthin had attracted growing scientific attention because of their concentration in the macula and their potential antioxidant and light-filtering properties.

Observational research also suggested that people consuming greater amounts of these carotenoids might have a lower risk of certain forms of AMD.

But observational associations are not the same as proof from randomized clinical trials.

Researchers therefore needed to determine whether supplementing lutein and zeaxanthin would provide additional clinical benefit beyond the original AREDS formulation.

This became one of the central questions of AREDS2.

3. Researchers Wanted to Test Omega-3 Fatty Acids

Omega-3 fatty acids — particularly DHA and EPA — were also of interest.

DHA is an important structural component of retinal cell membranes, and observational studies had raised the possibility that diets rich in omega-3 fatty acids might be associated with lower AMD risk.

AREDS2 therefore tested whether adding DHA and EPA to the original formulation could further reduce progression to advanced AMD.

This was another important example of why randomized clinical trials matter.

A nutrient can have a plausible biological role and appear promising in observational research without necessarily producing additional benefit when tested as a supplement.

AREDS2 would eventually demonstrate exactly that distinction.

The Main Questions AREDS2 Tried to Answer

AREDS2 was designed around several practical questions:

Could lutein and zeaxanthin improve the original AREDS formula?

Could omega-3 fatty acids provide additional protection?

Could beta-carotene safely be removed?

Could the amount of zinc be reduced without reducing effectiveness?

To answer those questions, researchers enrolled 4,203 participants between the ages of 50 and 85.

Unlike the original study, AREDS2 specifically recruited people already considered at relatively high risk of AMD progression — primarily those with intermediate AMD in both eyes or intermediate AMD in one eye and advanced AMD in the other.

The stage was now set for one of the most important refinements in nutritional eye research.

And the results would turn out to be more complicated — and more informative — than simply showing that adding more nutrients was better.

What Did AREDS2 Actually Find?

AREDS2 was designed to answer a straightforward question:

Could the original AREDS formula be improved?

Researchers tested several possibilities.

They examined whether adding:

• lutein + zeaxanthin
• DHA + EPA omega-3 fatty acids
• or both

would further reduce the risk of progression to advanced AMD.

They also tested whether the original formula could be modified by:

• removing beta-carotene;
• reducing zinc from 80 mg to 25 mg;
• or making both changes at the same time.

The results were important — but they were not as simple as “more nutrients produced more protection.”

In the primary AREDS2 analysis, adding lutein and zeaxanthin, omega-3 fatty acids, or both to the original AREDS formulation did not produce a statistically significant additional reduction in progression to advanced AMD compared with the control formulation.

That finding is essential when interpreting AREDS2.

It means the study did not show that simply adding more ingredients to an already established nutritional formula automatically produced better clinical outcomes.

However, when researchers looked more closely at how different carotenoid formulations performed, the picture became more interesting.

Lutein and Zeaxanthin: More Nuanced Than the Headline Result

In the main AREDS2 analysis, adding 10 mg of lutein and 2 mg of zeaxanthin to the original AREDS formulation did not significantly lower the overall risk of progression to advanced AMD.

The five-year probability of progression was approximately:

• 31% in the control group;
• 29% in the lutein + zeaxanthin group;
• 31% in the DHA + EPA group;
• 30% in the group receiving both lutein + zeaxanthin and DHA + EPA.

The difference for lutein and zeaxanthin did not reach statistical significance in the primary comparison.

At first glance, that might appear to suggest that lutein and zeaxanthin offered little value.

But AREDS2 was designed in a way that allowed researchers to examine another important question:

What happens if lutein and zeaxanthin replace beta-carotene rather than simply being added on top of it?

That analysis produced a different result.

Participants who received an AREDS formulation containing lutein and zeaxanthin without beta-carotene had a lower risk of progression to advanced AMD compared with participants receiving beta-carotene without lutein and zeaxanthin.

The National Eye Institute reports an approximately 18% lower risk in that comparison.

For a broader look at the nutrients commonly studied for visual health, see our guide to Eye Vitamins and Nutrients: What Actually Supports Healthy Vision?

That finding became one of the most important practical outcomes of AREDS2.

Why Replacing Beta-Carotene Mattered

Beta-carotene had been included in the original AREDS formula as an antioxidant.

However, by the time AREDS2 was designed, evidence from other clinical trials had raised concerns about high-dose beta-carotene supplementation in smokers.

Specifically, beta-carotene had been associated with an increased risk of lung cancer among people who smoked.

AREDS2 therefore excluded current smokers from receiving study formulations containing beta-carotene.

Former smokers could still receive them.

During the trial, lung cancer occurred more frequently among participants assigned to formulations containing beta-carotene.

In the primary AREDS2 publication, lung cancer was reported in approximately:

• 2.0% of participants assigned beta-carotene;
• compared with 0.9% of those not assigned beta-carotene.

Most of the lung cancers occurred in former smokers.

This finding helped strengthen the rationale for replacing beta-carotene with lutein and zeaxanthin.

The modern AREDS2 formulation therefore contains:

• vitamin C;
• vitamin E;
• zinc;
• copper;
• lutein;
• zeaxanthin;

and does not contain beta-carotene.

For current and former smokers, this difference is particularly important.

The National Eye Institute specifically advises these groups to avoid the original beta-carotene-containing AREDS formulation and use the AREDS2 formulation instead when supplementation is medically appropriate.

AREDS2 replaced beta-carotene with lutein and zeaxanthin after safety concerns emerged regarding beta-carotene supplementation in smokers and former smokers.

What About People With Low Dietary Lutein and Zeaxanthin?

AREDS2 also produced an interesting finding when researchers examined participants according to their usual dietary intake.

Among participants who had the lowest dietary intake of lutein and zeaxanthin, those assigned supplemental lutein and zeaxanthin experienced a lower risk of progression to advanced AMD compared with participants with similarly low dietary intake who did not receive those supplements.

The National Eye Institute reports that the risk was approximately 26% lower in this subgroup.

This result is important, but it needs to be interpreted carefully.

It came from a subgroup analysis rather than the study’s primary overall comparison.

That means it should not be interpreted as proof that everyone with a low dietary intake will experience exactly the same benefit.

Instead, it provides supporting evidence that baseline nutritional status may influence how people respond to supplementation.

This is a useful example of why clinical nutrition research often requires more nuance than a simple “works” or “does not work” conclusion.

What Happened With Omega-3 Fatty Acids?

Omega-3 fatty acids were among the most anticipated components of AREDS2.

The trial used:

• 350 mg DHA
• 650 mg EPA

per day.

Researchers included these nutrients because observational studies had suggested that people who consumed more fish or omega-3 fatty acids might have a lower risk of developing advanced AMD.

The biological rationale also seemed plausible.

DHA is highly concentrated in retinal tissue and plays an important structural role in photoreceptor cell membranes.

But randomized clinical testing produced a different result.

Adding DHA and EPA to the AREDS formulation did not significantly reduce progression to advanced AMD.

The National Eye Institute summarizes the finding simply:

omega-3 supplementation did not provide an additional benefit for AMD in AREDS2.

This does not mean that omega-3 fatty acids have no biological role in the eye.

Nor does it mean that consuming fish as part of a balanced diet has no health value.

It means something much narrower:

the specific DHA + EPA supplementation regimen tested in AREDS2 did not add measurable protection against AMD progression on top of the AREDS formulation.

That distinction is important.

Dietary associations, biological plausibility, and results from randomized supplementation trials are different forms of evidence.

They should not automatically be treated as interchangeable.

Why the Omega-3 Result Matters

The omega-3 findings illustrate one of the strongest lessons from AREDS2:

A nutrient can make biological sense without necessarily improving a clinical outcome when added as a supplement.

Before AREDS2, observational evidence made omega-3 fatty acids appear promising.

But randomized controlled trials are designed specifically to test whether an intervention itself causes a measurable difference.

AREDS2 did not demonstrate that additional benefit.

This is precisely why high-quality clinical trials are so important when evaluating supplement claims.

A marketing statement such as:

“Omega-3s are present in the retina, therefore omega-3 supplements prevent AMD”

would skip several important steps in the evidence.

AREDS2 showed why those steps matter.

Did Lowering Zinc Change the Results?

The original AREDS formula contained 80 mg of zinc, a relatively high supplemental dose.

Researchers questioned whether that amount was necessary.

AREDS2 therefore compared the original zinc level of 80 mg with a lower dose of 25 mg.

The trial did not find a statistically significant difference in the effectiveness of the formulation when the zinc dose was reduced.

This means AREDS2 did not demonstrate that 80 mg produced a clearly greater protective effect than 25 mg within the trial.

However, the commercially recognized AREDS2 formula continues to use the original 80 mg zinc dose, along with 2 mg of copper.

That point sometimes causes confusion.

The trial showed that lowering zinc did not significantly change the overall outcome, but that does not mean individuals should independently alter an AREDS2 regimen.

The doses used in AREDS2 are substantially higher than those found in an ordinary multivitamin, which is another reason supplementation should be discussed with an eye-care professional.

Why Is Copper Included in AREDS2?

Copper is sometimes overlooked when people discuss the AREDS2 formula.

It was not included primarily because researchers believed it directly slowed AMD progression.

Instead, copper was added to help address a nutritional consequence of high-dose zinc supplementation.

Long-term high zinc intake can interfere with copper absorption.

The AREDS and AREDS2 formulations therefore included:

2 mg of copper as cupric oxide

to reduce the risk of zinc-related copper deficiency.

This is another useful reminder that supplement formulas are not simply collections of individual “eye nutrients.”

The ingredients can interact with one another, and the formulation needs to be considered as a whole.

AREDS vs. AREDS2: What Actually Changed?

The simplest way to understand the evolution from AREDS to AREDS2 is to compare the final formulas directly.

Nutrient	Original AREDS	AREDS2
Vitamin C	500 mg	500 mg
Vitamin E	400 IU	400 IU
Beta-carotene	15 mg	—
Lutein	—	10 mg
Zeaxanthin	—	2 mg
Zinc	80 mg	80 mg
Copper	2 mg	2 mg

The transition from AREDS to AREDS2 replaced beta-carotene with lutein and zeaxanthin while retaining the core antioxidant and mineral components.

The most visible difference is straightforward:

beta-carotene was removed, while lutein and zeaxanthin were added.

Omega-3 fatty acids were investigated but ultimately were not included in the standard AREDS2 formulation, because they did not provide an additional benefit in the trial.

The AREDS2 formula therefore was not simply a larger version of AREDS.

It was a refinement.

Researchers preserved the components with established evidence, replaced a carotenoid associated with safety concerns, and excluded an added intervention that failed to improve the primary clinical outcome.

That process is a useful example of how evidence-based medicine evolves.

The goal is not necessarily to add more ingredients.

Sometimes better evidence leads to a simpler and safer formulation.

AREDS2 Did Not Make the Original AREDS Finding Obsolete

It is also important to understand that AREDS2 did not invalidate the original AREDS study.

The two trials answered related but different questions.

AREDS asked:

Can a combination of antioxidants and minerals reduce progression to advanced AMD in high-risk individuals?

The answer was yes.

AREDS2 then asked:

Can that formulation be improved or made safer?

The answer was more nuanced.

Adding lutein and zeaxanthin or omega-3 fatty acids on top of the original formula did not significantly improve the primary outcome.

But replacing beta-carotene with lutein and zeaxanthin provided a safer carotenoid strategy and showed evidence of comparable or better protection in several analyses.

Reducing zinc did not significantly alter efficacy.

And adding omega-3 supplements did not produce additional protection.

Together, the two trials created the evidence base behind the modern AREDS2 formulation.

A Key Lesson From AREDS2

One of the most valuable lessons from the study is broader than eye health.

More nutrients do not automatically mean more benefit.

AREDS2 tested ingredients that had plausible biological mechanisms and promising observational evidence.

Some ultimately strengthened the formulation.

Others did not.

Lutein and zeaxanthin became important primarily as replacements for beta-carotene.

Omega-3 fatty acids did not improve AMD outcomes when added to the formula.

Lower zinc performed similarly to the original dose in the trial.

And beta-carotene presented a meaningful safety concern for people with a history of smoking.

This is exactly why individual ingredients should not be judged only by whether they are associated with eye biology.

What matters clinically is whether a well-designed trial shows that they change an outcome that actually matters to patients.

What AREDS and AREDS2 Did NOT Prove

AREDS and AREDS2 produced some of the strongest clinical evidence available for nutritional supplementation in age-related macular degeneration.

But strong evidence does not mean unlimited evidence.

The trials answered specific questions in specific groups of people.

Understanding what the studies did not prove is just as important as understanding what they did.

AREDS2 supported reduced AMD progression risk in specific patients and the replacement of beta-carotene, but did not show prevention of AMD in healthy adults, restoration of lost vision, or added AMD benefit from omega-3 supplements

AREDS2 Did Not Show That Everyone Should Take Eye Supplements

Perhaps the most important limitation is that AREDS2 was never intended as a general supplement recommendation for everyone concerned about aging eyes.

The National Eye Institute states that AREDS and AREDS2 formulations benefited people with intermediate or late AMD, while no benefit was demonstrated for people with early AMD or for those without AMD.

This means AREDS2 should not be interpreted as evidence that every older adult needs a high-dose eye supplement.

Someone who has healthy eyes, mild age-related changes, digital eye strain, dry eye symptoms, or simple refractive problems is not automatically part of the population in which AREDS2 demonstrated benefit.

The evidence is much more specific.

AREDS2 Did Not Prevent AMD From Developing

Another common misunderstanding is that AREDS2 supplementation can prevent age-related macular degeneration.

The clinical trials did not demonstrate that.

According to the National Eye Institute:

AREDS and AREDS2 supplements do not prevent the onset of AMD.

Instead, their strongest demonstrated role is helping reduce progression from intermediate AMD to advanced AMD.

That difference is crucial.

Prevention asks:

Can this intervention stop a disease from developing in someone who does not already have it?

Progression asks:

Can this intervention slow the worsening of a disease that is already present?

AREDS2 evidence primarily supports the second question.

AREDS2 Did Not Show a Benefit for Early AMD

Early AMD is another area where supplement claims can easily become broader than the evidence.

The National Eye Institute states that AREDS2 supplements have not been shown to prevent early AMD from progressing to intermediate AMD.

For people diagnosed with early AMD, regular monitoring remains important.

A dilated eye examination allows an eye-care professional to watch for structural changes and determine whether the condition progresses to a stage where AREDS2 supplementation may become appropriate.

This is one reason AMD stage matters so much.

Two people can both be told they have “macular degeneration” while having very different levels of disease and very different clinical needs.

AREDS2 Did Not Restore Lost Vision

Neither AREDS nor AREDS2 should be interpreted as vision-restoration therapies.

The nutrients were studied for their ability to influence the risk of disease progression, not to regenerate damaged retinal tissue.

If AMD has already caused structural damage to the macula, nutritional supplementation should not be expected to restore those damaged cells or return vision to its previous level.

This distinction is especially important when evaluating claims that supplements can:

• “reverse macular degeneration”;
• “restore eyesight”;
• “repair the retina”;
• or “bring back lost vision.”

Those claims go considerably beyond what the AREDS trials demonstrated.

AREDS2 Did Not Show That More Nutrients Are Always Better

AREDS2 provides an excellent example of why supplement formulations should be evaluated clinically rather than simply by ingredient count.

Researchers tested several additional nutrients.

Some produced useful findings.

Others did not.

For example, adding omega-3 fatty acids to the established AREDS formulation did not significantly reduce progression to advanced AMD.

Similarly, simply adding lutein and zeaxanthin to the original formula did not significantly improve the primary overall outcome.

Their value became clearer when researchers evaluated them as replacements for beta-carotene and examined specific subgroups.

The lesson is straightforward:

A supplement containing more ingredients is not automatically supported by stronger evidence.

Clinical benefit depends on the formulation, dose, population, and health outcome being studied.

AREDS2 Did Not Prove That Every “Eye Health” Ingredient Works

Modern eye supplements frequently contain long combinations of nutrients such as:

• lutein;
• zeaxanthin;
• astaxanthin;
• bilberry;
• saffron;
• omega-3 fatty acids;
• vitamin A;
• zinc;
• selenium;
• various plant extracts;
• and other antioxidants.

Some of these compounds have interesting research behind them.

But the AREDS2 trial should not be used as evidence for ingredients that were not demonstrated to improve its clinical outcomes.

In particular, a supplement cannot simply claim to be “supported by AREDS2 research” because it contains one ingredient that appeared in the trial.

Evidence applies most directly to the specific formulation and clinical context that were studied.

That principle matters enormously when comparing supplements.

Who Should Consider AREDS2 Supplements?

The answer depends primarily on the stage of AMD.

According to the National Eye Institute, AREDS2 supplementation may be appropriate for people with:

• intermediate AMD in one or both eyes, or
• late AMD in one eye, where supplementation may help slow progression in the other eye.

AREDS2 evidence is strongest for people with intermediate AMD and may also be relevant when late AMD is present in one eye.

These are the populations in which the evidence is strongest.

AREDS2 is therefore better understood as a targeted nutritional intervention rather than a general-purpose eye vitamin.

Intermediate AMD

People with intermediate AMD are among the main groups for whom AREDS2 may provide meaningful benefit.

At this stage, structural changes such as larger drusen or pigment abnormalities may indicate a greater likelihood of progressing to advanced disease.

AREDS and AREDS2 showed that nutritional supplementation could reduce this progression risk.

The National Eye Institute summarizes the effect as an approximately 25% reduction in progression from intermediate to advanced AMD.

That does not eliminate the risk.

It modifies it.

Regular ophthalmic monitoring remains necessary even when supplementation is used.

Late AMD in One Eye

AREDS2 may also be useful when someone has late AMD in one eye but not the other.

In this situation, supplementation may help reduce the likelihood that the less-affected eye progresses to advanced AMD.

Preserving function in the better-seeing eye can obviously have substantial practical importance.

But supplementation is still only one component of care.

The person may also require:

• regular retinal examinations;
• imaging;
• monitoring with an Amsler grid or similar methods;
• and, depending on the type of AMD, additional medical treatment.

What If Someone Already Has Late AMD in Both Eyes?

The National Eye Institute states that AREDS2 supplements probably do not provide the same benefit when late AMD is already present in both eyes.

At that point, the clinical focus may shift toward managing the disease itself and maximizing remaining vision.

Depending on the type of AMD, this may include medical treatment or low-vision rehabilitation.

Again, this illustrates why simply asking:

“Is AREDS2 good for the eyes?”

is not specific enough.

The more relevant question is:

“Does the evidence apply to this particular stage of AMD?”

Who Should Not Assume AREDS2 Is Appropriate?

Several groups should not automatically assume that an AREDS2 supplement is beneficial simply because it is sold as an eye-health product.

These include people with:

• no AMD;
• early AMD;
• uncomplicated age-related vision changes;
• presbyopia;
• digital eye strain;
• dry eye symptoms;
• myopia or hyperopia;
• cataracts without AMD;
• or other unrelated eye conditions.

AREDS2 was not designed to treat those conditions.

That does not necessarily mean nutritional status is irrelevant to overall eye health.

It means that AREDS2 evidence cannot automatically be transferred to unrelated conditions.

AREDS2 Is Not a Standard Multivitamin

Another important point is dosage.

AREDS2 contains substantially higher amounts of several nutrients than would normally be found in an ordinary multivitamin.

The standard formulation studied contains:

Nutrient	AREDS2 Amount
Vitamin C	500 mg
Vitamin E	400 IU
Zinc	80 mg
Copper	2 mg
Lutein	10 mg
Zeaxanthin	2 mg

These doses are not intended to represent ordinary daily nutritional requirements.

They are part of a specific clinical formulation studied in people at increased risk of AMD progression.

That distinction also means someone should not assume that taking several separate supplements that happen to contain these nutrients is equivalent to using an AREDS2 formulation.

Medication and Supplement Interactions Matter

High-dose nutritional supplements can interact with medications or influence the absorption and metabolism of other nutrients.

The National Eye Institute specifically notes that AREDS2 contains large quantities of vitamins and minerals and recommends discussing supplementation with a healthcare provider, particularly when other medications or supplements are being used.

Vitamin E, for example, can interact with certain medications.

High-dose zinc can also affect nutrient balance, which is one reason copper is included in the AREDS2 formulation.

This is another reason AREDS2 should not be treated like an ordinary food supplement taken casually “just in case.”

Current and Former Smokers: Why the Formula Matters

Smoking history deserves special attention.

The original AREDS formula contained 15 mg of beta-carotene.

Evidence linking high-dose beta-carotene supplementation with lung cancer risk in smokers led researchers to investigate alternatives during AREDS2.

The National Eye Institute now specifically advises current and former smokers to use the AREDS2 formulation rather than the original AREDS formula containing beta-carotene when supplementation is appropriate.

Modern AREDS2 formulations replace beta-carotene with:

• 10 mg lutein
• 2 mg zeaxanthin

This was not merely a marketing reformulation.

It was a change supported by clinical evidence and safety considerations.

What About Cataracts?

AREDS and AREDS2 are sometimes discussed as though they provided broad protection against multiple age-related eye diseases.

That interpretation is inaccurate.

The National Eye Institute summarizes the primary evidence clearly:

AREDS and AREDS2 supplementation did not produce an overall protective effect against cataracts.

That is particularly interesting because antioxidant nutrients had long been investigated for potential roles in age-related lens changes.

The large randomized trials, however, did not demonstrate the same overall benefit for cataracts that was observed for AMD progression.

There was an interesting subgroup observation in AREDS2 involving participants with very low dietary lutein and zeaxanthin intake, but that finding should not be interpreted as evidence that AREDS2 supplements generally prevent cataracts.

The broader conclusion remains:

The strongest established clinical role of AREDS2 is AMD progression — not cataract prevention.

AREDS2 Does Not Replace Medical Treatment

AREDS2 supplements are also not substitutes for treatments used in advanced forms of AMD.

For example, some people with wet AMD may require treatments specifically directed at abnormal blood-vessel growth and retinal leakage.

Nutritional supplementation serves a different purpose.

It may help modify long-term progression risk in appropriate patients, but it does not replace treatments directed at active disease.

Someone experiencing new symptoms such as:

• sudden central blur;
• distorted straight lines;
• a new dark or blank area in central vision;
• or rapid changes in visual function

should seek professional eye care rather than relying on nutritional supplementation.

How Should Consumers Interpret “AREDS2 Formula” on a Supplement Label?

The phrase “AREDS2 formula” has become common in the supplement market.

But consumers should look beyond the front of the bottle.

A formulation modeled on the research should contain the nutrients studied in the established amounts:

• 500 mg vitamin C;
• 400 IU vitamin E;
• 10 mg lutein;
• 2 mg zeaxanthin;
• 80 mg zinc;
• 2 mg copper;
• and no beta-carotene.

The National Eye Institute recommends checking the ingredient list because products marketed for eye health are not necessarily identical to the formulation evaluated in the clinical research.

Terms such as:

“eye support,”
“macular support,”
“vision formula,”
or “inspired by AREDS2”

do not necessarily mean that a product duplicates the research formulation.

The actual ingredient amounts matter.

Evidence Interpretation: What AREDS2 Really Tells Us

AREDS and AREDS2 provide unusually strong evidence within the supplement field because they were large, randomized clinical trials conducted around clearly defined medical outcomes.

But their strength comes partly from their specificity.

The research does not tell us that:

all antioxidants protect vision;

all eye supplements prevent AMD;

everyone should take lutein and zeaxanthin;

or

taking more nutrients provides greater protection.

What the evidence supports is much narrower — and therefore more useful.

For certain people with intermediate AMD or advanced disease affecting one eye, a specific combination of nutrients can reduce the likelihood of progression to advanced AMD.

AREDS2 then improved that strategy by replacing beta-carotene with lutein and zeaxanthin and confirming that omega-3 supplementation did not add measurable protection in the trial.

That is a meaningful clinical finding.

But it should remain within the boundaries established by the research.

The real lesson from AREDS2 is therefore not simply:

“eye vitamins work.”

A more accurate lesson is:

when the right nutrients are studied in the right doses, in the right population, against a clearly defined clinical outcome, nutritional supplementation can sometimes produce a measurable benefit.

That is a much stronger foundation for evaluating eye-health supplements than relying on ingredient lists, biological plausibility, or marketing claims alone.

AREDS2 vs. General Eye-Health Supplements

One of the easiest mistakes to make when reading about eye supplements is to treat every formula containing lutein, zeaxanthin, zinc, or antioxidants as though it were an AREDS2 supplement.

That is not how the evidence works.

AREDS2 refers to a very specific formulation studied in people with particular stages of age-related macular degeneration.

The established AREDS2 formula contains:

• Vitamin C — 500 mg
• Vitamin E — 400 IU
• Lutein — 10 mg
• Zeaxanthin — 2 mg
• Zinc — 80 mg
• Copper — 2 mg

It does not contain beta-carotene. The National Eye Institute advises consumers looking for an AREDS2 supplement to check that the ingredient amounts match the studied formulation.

A general eye-health supplement may contain some of these same nutrients while using different doses, additional ingredients, or an entirely different nutritional strategy.

That does not necessarily make the formula better or worse.

It simply means that it should not automatically be considered equivalent to AREDS2.

Sharing Ingredients Does Not Mean Sharing the Same Evidence

Consider lutein.

AREDS2 contains 10 mg of lutein.

Many other eye-health supplements also contain lutein because it is naturally concentrated in the macula and has been widely investigated for its role in ocular nutrition.

But the presence of 10 mg of lutein by itself does not transform a supplement into an AREDS2 formulation.

The same principle applies to zeaxanthin, zinc, vitamin C, vitamin E, or any other nutrient.

Clinical evidence applies most directly to:

the formulation that was studied,
at the doses that were studied,
in the population that was studied,
for the clinical outcome that was measured.

This distinction becomes especially important when supplement advertising references AREDS2 research.

A product may legitimately discuss research involving individual carotenoids without being an AREDS2 formula.

What would be misleading is treating the AREDS2 results as though they proved that any supplement containing lutein or zeaxanthin will reduce AMD progression by the same amount.

AREDS2 Has a Disease-Specific Purpose

Another major difference is the purpose of the formulation.

AREDS2 was developed primarily around one clinical objective:

reducing the risk of progression to advanced AMD in people already at elevated risk.

The National Eye Institute continues to report an approximately 25% reduction in progression from intermediate to advanced AMD with AREDS/AREDS2 supplementation in the relevant population.

A general eye-health supplement may instead be formulated around broader nutritional goals, such as supporting:

• macular carotenoid intake;
• antioxidant defenses;
• retinal nutrition;
• healthy aging;
• or general visual function.

Those are different objectives.

Therefore, when comparing two products, asking only:

“Which one has more eye-health ingredients?”

misses the central issue.

A better question is:

“What is this particular formulation designed to do, and what evidence supports that purpose?”

Where Does Advanced Vision Formula Fit?

Advanced Vision Formula is a useful example of why this distinction matters.

The product is marketed as a general eye-health supplement, not as the standardized AREDS2 clinical formulation.

According to the manufacturer’s current product information, Advanced Vision Formula contains 15 nutrients and includes ingredients such as:

• lutein;
• zeaxanthin;
• astaxanthin;
• bilberry;
• Cognizin® citicoline;
• ginkgo biloba;
• taurine;
• and other nutritional compounds intended to support eye health.

The manufacturer’s current formula lists 10 mg of lutein and 3 mg of zeaxanthin per daily serving.

Those carotenoids are highly relevant to eye nutrition.

But that does not make Advanced Vision Formula an AREDS2 formula.

The AREDS2 clinical formulation contains a particular combination of vitamin C, vitamin E, zinc, copper, lutein, and zeaxanthin at specific doses.

Advanced Vision Formula follows a different formulation strategy.

That distinction should remain clear.

For a complete breakdown of the formula, ingredients, evidence, limitations, and product positioning, see our Advanced Vision Formula Review.

Advanced Vision Formula and AREDS2 Should Not Be Treated as Interchangeable

A person diagnosed with intermediate AMD should not assume that any general eye-health supplement can replace an AREDS2 formulation recommended by an eye-care professional.

Likewise, AREDS2 should not be treated as though it were designed to cover every aspect of nutritional eye support.

The products serve different conceptual purposes.

AREDS2 is built around a specific clinical research protocol for people at increased risk of AMD progression.

A general eye-health formula may combine nutrients investigated for broader aspects of ocular nutrition but may not have been tested as a complete formulation in an AREDS-style clinical trial.

This is especially important for readers evaluating products after receiving an AMD diagnosis.

The presence of lutein and zeaxanthin alone is not enough to establish therapeutic equivalence.

Why Lutein and Zeaxanthin Still Matter Beyond AREDS2

None of this diminishes the scientific interest surrounding lutein and zeaxanthin.

These carotenoids are naturally concentrated in the retina, particularly in the macular region, and contribute to macular pigment.

You can learn more about this protective retinal pigment in What Is Macular Pigment and Why Does It Matter for Vision?

They are among the most extensively studied dietary carotenoids in eye-health research.

AREDS2 also reinforced their relevance by establishing them as the preferred replacements for beta-carotene within the modern AREDS2 formulation.

To explore these carotenoids in greater detail, including their dietary sources and biological roles in the retina, read our guide to Lutein and Zeaxanthin: Evidence-Based Guide to Eye Health.

However, there is an important difference between saying:

lutein and zeaxanthin are important carotenoids studied in eye health

and saying:

any supplement containing lutein and zeaxanthin provides the same clinical protection demonstrated by AREDS2.

Only the first statement accurately reflects the broader evidence.

How to Evaluate an Eye Supplement After Learning About AREDS2

AREDS2 offers readers a useful framework for looking beyond marketing.

Rather than judging a supplement by the number of ingredients on the label, consider several separate questions.

1. What Is the Formula Designed For?

Is the supplement specifically intended to reproduce the AREDS2 formulation for people with appropriate stages of AMD?

Or is it a broader nutritional formula designed for general eye-health support?

Those are not the same category.

2. Does the Product Match the Studied Formula?

When a product is marketed as an AREDS2 supplement, compare its label with the clinical formulation:

• 500 mg vitamin C;
• 400 IU vitamin E;
• 10 mg lutein;
• 2 mg zeaxanthin;
• 80 mg zinc;
• 2 mg copper.

The National Eye Institute specifically recommends checking the amounts rather than relying only on front-label terminology.

3. Are Claims Based on the Complete Formula or Individual Ingredients?

This is a crucial distinction.

Research on lutein does not automatically validate every formula containing lutein.

Research on zeaxanthin does not prove every combination containing zeaxanthin.

And AREDS2 research does not validate unrelated ingredients simply because they appear in the same eye supplement.

Evidence should be matched to the claim being made.

4. Is the Evidence About Disease Progression or General Nutritional Support?

Supplement discussions often blur these concepts.

AREDS2 investigated a measurable disease outcome:

progression to advanced AMD.

Other studies may investigate outcomes such as:

• macular pigment optical density;
• visual performance;
• contrast sensitivity;
• oxidative stress markers;
• subjective eye fatigue;
• or nutrient status.

All of these outcomes may be scientifically interesting, but they are not equivalent.

Clinical disease progression generally represents a much stronger and more consequential endpoint than a laboratory or surrogate marker.

Why This Distinction Matters for the Advanced Vision Formula Review

When evaluating a product such as Advanced Vision Formula, AREDS2 should be used as context, not as borrowed proof.

For example, the fact that AREDS2 used lutein and zeaxanthin supports the broader scientific relevance of these carotenoids to eye-health research.

But it would be inappropriate to conclude that Advanced Vision Formula itself has been proven to reduce AMD progression simply because it contains those nutrients.

The correct approach is to evaluate its ingredients individually and then consider how the complete formulation fits within the broader scientific literature.

This is the same evidence-based standard that should be applied to any eye supplement.

AREDS2 Research vs. Ingredient Research

The distinction can be summarized simply:

Type of Evidence	What It Can Tell Us
AREDS/AREDS2 clinical trials	What the studied formulation did in specific AMD populations
Individual nutrient trials	What a particular nutrient may influence
Observational studies	Whether dietary or lifestyle patterns are associated with outcomes
Laboratory studies	Possible biological mechanisms
Product-specific clinical trial	What the finished product itself may do

These forms of evidence are not interchangeable.

A laboratory study may help explain why a nutrient is biologically interesting.

An observational study may identify an association worth investigating.

A randomized clinical trial can provide stronger evidence that an intervention caused a particular outcome.

And a trial conducted on one formulation cannot automatically be transferred to another.

Eye-supplement evidence should be interpreted by considering the ingredient, dose, study population, clinical trial design, and the outcome that actually changed

What AREDS2 Teaches Us About Supplement Marketing

AREDS2 also provides a valuable lesson for consumers navigating the supplement market.

The strongest claims are not necessarily attached to the strongest evidence.

Terms such as:

• “clinically researched ingredients”;
• “doctor-formulated”;
• “macular support”;
• “advanced eye nutrition”;
• or “contains AREDS2 nutrients”

can sound impressive.

But none of those phrases by themselves demonstrate that a finished product has reproduced the outcomes of the AREDS2 trial.

The key questions remain:

What exactly was studied?

At what dose?

In whom?

Compared with what?

And what outcome actually changed?

Those questions help separate legitimate scientific context from marketing extrapolation.

The Broader Meaning of AREDS2 for Eye Nutrition

AREDS2 remains important beyond the specific supplement formula because it demonstrated something relatively uncommon in nutritional research:

a carefully selected combination of nutrients produced a meaningful clinical benefit in a clearly defined group of patients.

At the same time, the study showed that nutritional science is rarely as simple as adding ingredients together.

Omega-3 fatty acids appeared promising but did not improve AMD outcomes when added to the formulation.

Lutein and zeaxanthin did not significantly improve the primary outcome when simply added to the original formula, but they proved valuable as replacements for beta-carotene.

Lowering zinc did not significantly alter efficacy.

And long-term follow-up continued to support the lutein-and-zeaxanthin modification over beta-carotene.

The most useful conclusion is therefore not that a particular nutrient is universally “good” or “bad.”

It is that clinical context matters.

AREDS2 addresses one specific aspect of age-related eye disease, but many other structural and functional changes can occur with age. Our guide to How the Eye Changes With Age explores those changes in greater detail.

The effectiveness of nutritional supplementation depends on the nutrient, dose, combination, population, health condition, and outcome being studied.

What Did the Long-Term AREDS2 Follow-Up Show?

The original AREDS2 trial followed participants for about five years.

But researchers continued to follow many participants afterward, which provided an opportunity to examine whether the differences between beta-carotene and lutein plus zeaxanthin persisted over a longer period.

A 10-year follow-up analysis published in 2022 provided an important update.

Researchers found that replacing beta-carotene with lutein and zeaxanthin continued to appear favorable over the longer term.

The National Eye Institute summarized the findings by noting that the AREDS2 formulation:

• maintained protection against progression to advanced AMD;
• avoided the increased lung-cancer concern associated with beta-carotene;
• and performed better than the original beta-carotene-containing formulation in long-term analyses.

This follow-up strengthened the rationale for the modern AREDS2 formulation rather than returning to the original AREDS combination.

Why Long-Term Follow-Up Matters

A five-year randomized clinical trial can provide strong evidence.

But age-related macular degeneration is a chronic condition that may progress over many years.

Long-term follow-up helps researchers determine whether:

• benefits persist;
• safety concerns become more apparent;
• delayed effects emerge;
• or conclusions change with additional time.

That is especially important for nutritional interventions, because people may take supplements for years or even decades.

The extended AREDS2 findings did not overturn the original conclusions.

Instead, they strengthened one of the most important changes made during AREDS2:

lutein and zeaxanthin are preferable to beta-carotene in the formulation.

Practical Takeaways From AREDS and AREDS2

After examining both studies, several conclusions stand out.

1. AREDS2 Is Not a General Vision Supplement Recommendation

The evidence applies primarily to people with specific stages of AMD.

It should not be interpreted as proof that everyone benefits from taking an AREDS2 supplement.

2. AREDS2 Helps Reduce Progression Risk — It Does Not Cure AMD

The benefit is about reducing the likelihood of progression to advanced disease.

AREDS2 does not:

• reverse macular degeneration;
• regenerate retinal tissue;
• restore lost vision;
• or eliminate the need for eye examinations and treatment.

3. Lutein and Zeaxanthin Replaced Beta-Carotene for Good Reasons

The change was not simply cosmetic.

AREDS2 and its long-term follow-up supported lutein and zeaxanthin as a safer carotenoid approach, particularly because beta-carotene was associated with increased lung-cancer risk among former smokers.

4. Omega-3 Supplements Did Not Add Protection in AREDS2

DHA and EPA were biologically plausible candidates and had observational research behind them.

But when tested in the randomized AREDS2 trial, they did not significantly reduce progression to advanced AMD when added to the AREDS formulation.

That does not mean omega-3 fatty acids are nutritionally irrelevant.

It means AREDS2 did not demonstrate additional AMD protection from the supplementation strategy it tested.

5. More Ingredients Do Not Automatically Mean Better Evidence

AREDS2 is a strong reminder that supplement quality cannot be judged simply by the length of an ingredient list.

Some additions did not improve outcomes.

One ingredient was removed because of safety concerns.

The final formulation emerged through testing rather than through adding as many nutrients as possible.

6. The Exact Formula Matters

When a product is presented as an AREDS2 supplement, readers should compare the label with the formulation used in the research.

The evidence cannot automatically be transferred to:

• different doses;
• incomplete versions of the formula;
• or general eye-health supplements containing only selected AREDS2 ingredients.

7. AMD Stage Matters More Than Marketing Language

The most important question is not whether a supplement says:

“macular support”

or

“advanced eye formula.”

The more important question is whether the individual belongs to the population in which AREDS2 actually demonstrated benefit.

That determination requires an eye examination.

Frequently Asked Questions

Is AREDS2 Proven to Prevent Macular Degeneration?

No.

AREDS2 has not been shown to prevent AMD from developing in people who do not have the disease.

Its strongest evidence involves reducing progression to advanced AMD in certain people who already have intermediate disease.

Can AREDS2 Improve Vision?

AREDS2 was not designed as a general vision-enhancement supplement.

It has not been shown to restore vision already lost to AMD.

Its main role is helping reduce progression risk in appropriate patients.

Is AREDS2 Helpful for Early AMD?

The evidence does not show a meaningful benefit for people with early AMD.

The benefit becomes more relevant once the disease has progressed to an intermediate stage.

Can Healthy Adults Take AREDS2 for Prevention?

AREDS2 was not studied as a general preventive supplement for healthy adults.

Because it contains relatively high doses of several nutrients, people should not assume that taking it “just in case” provides additional protection.

Why Did AREDS2 Remove Beta-Carotene?

Beta-carotene supplementation had been associated with increased lung-cancer risk among smokers.

AREDS2 also observed more lung cancers among participants assigned beta-carotene, with most cases occurring in former smokers.

Lutein and zeaxanthin therefore became the preferred carotenoids in the modern formulation.

Does AREDS2 Contain Omega-3?

No.

Omega-3 fatty acids were tested during AREDS2, but they did not provide significant additional protection against advanced AMD progression.

They were therefore not included in the standard AREDS2 formula.

Is Lutein Alone the Same as AREDS2?

No.

Lutein is one component of the formulation.

AREDS2 evidence applies to a specific combination of nutrients and clinical context, not simply to lutein by itself.

Is Advanced Vision Formula an AREDS2 Supplement?

No.

Advanced Vision Formula is a broader eye-health supplement with a different formulation.

Although it contains nutrients such as lutein and zeaxanthin, it should not be considered interchangeable with the clinical AREDS2 formula.

Can AREDS2 Replace Treatment for Wet AMD?

No.

AREDS2 supplements do not replace treatments directed at active wet AMD or other forms of advanced disease.

Someone undergoing treatment should continue to follow the recommendations of their ophthalmologist or retina specialist.

Should Smokers Use the Original AREDS Formula?

Current and former smokers should avoid the original beta-carotene-containing formulation.

The modern AREDS2 formula replaces beta-carotene with lutein and zeaxanthin, partly because of the lung-cancer concern associated with beta-carotene supplementation.

Author Perspective

The AREDS and AREDS2 studies are a valuable reminder that supplement research should be interpreted carefully.

It is tempting to reduce the findings to a simple message such as:

“eye vitamins work.”

But that would miss what makes these studies scientifically useful.

The real strength of AREDS2 is its specificity.

Researchers studied a defined formulation, in a defined population, for a defined disease outcome.

Some nutrients helped refine the formula.

Others did not improve the primary outcome.

And one ingredient — beta-carotene — was ultimately replaced because longer-term evidence favored a safer alternative.

For consumers, this provides a useful framework when evaluating eye supplements.

Rather than asking only whether a product contains popular eye-health ingredients, it is worth asking:

• What was actually studied?
• Was the complete product tested?
• What dose was used?
• Who participated in the research?
• And what clinical outcome changed?

Those questions can make the difference between understanding scientific evidence and simply repeating supplement marketing.

— Manoel Lages, Virtudes Digital

Final Thoughts

AREDS and AREDS2 are among the most important clinical trials ever conducted on nutritional supplementation and eye disease.

The original AREDS trial demonstrated that a combination of antioxidants and zinc could reduce progression to advanced AMD in people at relatively high risk.

AREDS2 then refined that approach.

It showed that simply adding more nutrients did not necessarily improve outcomes.

Omega-3 supplementation did not provide additional protection.

Lowering zinc did not produce a statistically significant difference in efficacy.

And replacing beta-carotene with lutein and zeaxanthin created a formulation that proved more appropriate from both a safety and long-term evidence perspective.

Perhaps the most important lesson is therefore not about any single vitamin or carotenoid.

It is about evidence matching the claim.

AREDS2 does not prove that every eye supplement works.

It does not prove that everyone needs supplementation.

And it does not transform every formula containing lutein and zeaxanthin into an AREDS2 equivalent.

What it does provide is strong evidence that a specific nutritional intervention can help reduce progression to advanced AMD in a defined group of people.

That is a meaningful finding — and one that deserves to be presented accurately.

Medical Disclaimer

This article is for educational and informational purposes only and is not intended to provide medical advice, diagnosis, or treatment.

AREDS2 supplements contain relatively high amounts of certain vitamins and minerals and may not be appropriate for everyone. People with age-related macular degeneration, other eye conditions, chronic health conditions, or those taking medications or additional supplements should discuss supplementation with a qualified healthcare professional or eye-care specialist.

Never use dietary supplements as a substitute for professional eye examinations, prescribed medications, or medically recommended treatment.

Seek prompt professional evaluation if you experience sudden vision loss, new distortion, a dark or blank area in your central vision, flashes, floaters, or any significant change in visual function.

References

Age-Related Eye Disease Study Research Group.
A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS Report No. 8. Archives of Ophthalmology. 2001;119(10):1417–1436.

Age-Related Eye Disease Study 2 Research Group.
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–2015.

Chew EY, Clemons TE, Agrón E, et al.
Long-term outcomes of adding lutein/zeaxanthin and omega-3 fatty acids to the AREDS supplements on age-related macular degeneration progression. JAMA Ophthalmology. 2022.

National Eye Institute.
Age-Related Eye Disease Studies (AREDS/AREDS2). National Institutes of Health.

National Eye Institute.
AREDS/AREDS2 Frequently Asked Questions. National Institutes of Health.

National Eye Institute.
Nutritional Supplements for Age-Related Macular Degeneration. National Institutes of Health.

National Eye Institute.
NIH Study Confirms Benefit of Supplements for Slowing Age-Related Macular Degeneration. June 2, 2022.